Skip to main content
Article thumbnail
Location of Repository

Biomarkers of Induced Active and Passive Smoking Damage

By Maura Lodovici and Elisabetta Bigagli

Abstract

In addition to the well-known link between smoking and lung cancer, large epidemiological studies have shown a relationship between smoking and cancers of the nose, oral cavity, oropharynx, larynx, esophagus, pancreas, bladder, kidney, stomach, liver, colon and cervix, as well as myeloid leukemia. Epidemiological evidence has reported a direct link between exposure of non-smokers to environmental tobacco smoke and disease, most notably, lung cancer. Much evidence demonstrates that carcinogenic-DNA adducts are useful markers of tobacco smoke exposure, providing an integrated measurement of carcinogen intake, metabolic activation, and delivery to the DNA in target tissues. Monitoring accessible surrogate tissues, such as white blood cells or bronchoalveolar lavage (BAL) cells, also provides a means of investigating passive and active tobacco exposure in healthy individuals and cancer patients. Levels of DNA adducts measured in many tissues of smokers are significantly higher than in non-smokers. While some studies have demonstrated an association between carcinogenic DNA adducts and cancer in current smokers, no association has been observed in ex or never smokers. The role of genetic susceptibility in the development of smoking related-cancer is essential. In order to establish whether smoking-related DNA adducts are biomarkers of tobacco smoke exposure and/or its carcinogenic activity we summarized all data that associated tobacco smoke exposure and smoking-related DNA adducts both in controls and/or in cancer cases and studies where the effect of genetic polymorphisms involved in the activation and deactivation of carcinogens were also evaluated. In the future we hope we will be able to screen for lung cancer susceptibility by using specific biomarkers and that subjects of compared groups can be stratified for multiple potential modulators of biomarkers, taking into account various confounding factors

Topics: Review
Publisher: Molecular Diversity Preservation International (MDPI)
OAI identifier: oai:pubmedcentral.nih.gov:2672383
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (1997). 32P-postlabelling of aromatic DNA adducts in white blood cells and alveolar macrophages of smokers: saturation at high exposures.
    2. (1995). A molecular epidemiological case-control study of lung cancer. Cancer Epidemiol. Biomark Prev.
    3. (1982). A pilot project in molecular cancer epidemiology: determination of benzo[a]pyrene-DNA adducts in animal and human tissues by immunoassays. Carcinogenesis
    4. (1984). Activation of c-Ha-ras-1 proto-oncogene by in vitro modification with a chemical carcinogen, benzo(a)pyrene diol-epoxide. Nature
    5. (2005). Active and passive smoking and lifestyle determinants of 8-oxo-7,8-dihydro-2'-deoxyguanosine levels in human leukocyte DNA. Cancer Epidemiol. Biomarkers Prev.
    6. (2009). Agency for Research on Cancer): Tobacco smoking and involuntary smoking. ARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Available at http://monographs.iarc.fr/ENG/Monographs/vol83/volume83.pdf (Accessed
    7. (1992). An improved fluorometric assay for dosimetry of benzo(a)pyrene diol-epoxideDNA adducts in smokers' lung: comparisons with total bulky adducts and aryl hydrocarbon hydroxylase activity. Cancer Res.
    8. (2000). Analysis of aromatic DNA adducts and 7,8-dihydro-8-oxo-2’ deoxyguanosine in lymphocyte DNA from a case-control study of lung cancer involving minority populations.
    9. (2008). Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco
    10. (2002). Aromatic DNA adduct levels in coke oven workers: correlation with polymorphisms
    11. (1996). Aromatic DNA adducts in lymphocytes of humans working at high and low traffic density areas.
    12. (2001). Association between carcinogen-DNA adducts in white blood cells and lung cancer risk in the physicians health study. Cancer Res.
    13. (2009). Associations between smoking, GST genotypes and N7-methylguanine levels in DNA extracted from bronchial lavage cells.
    14. (1999). Benzo(a)pyrene diol-epoxide-DNA adduct levels and aryl hydrocarbon hydroxylase (AHH) in human white blood cells from smokers and non-smokers. Biomarkers
    15. (2004). Benzo(a)pyrene diolepoxide (BPDE)-DNA adduct levels in leukocytes of smokers in relation to polymorphism of CYP1A1, GSTM1, GSTP1, GSTT1, and mEH. Cancer Epidemiol. Biomarkers Prev.
    16. (1998). Benzo[a]pyrene diol-epoxide DNA adducts and levels of polycyclic aromatic hydrocarbons in autoptic samples from human lungs.
    17. (1991). Benzo[a]pyrene diolepoxide-DNA adducts in alveolar macrophages of smokers. Carcinogenesis
    18. (1987). Biological markers in environmental health research.
    19. (2003). Bulky DNA adducts and risk of cancer: a meta-analysis Cancer Epidemiol. Biomarkers Prev.
    20. (2006). Bulky DNA adducts as risk indicator of lung cancer in a Danish case-cohort study.
    21. (1997). California Environmental Protection Agency. Health effects of exposure to environmental tobacco smoke. Final Draft. California Environmental Protection Agency,
    22. (1998). Carcinogen DNA and protein adducts as biomarkers of human exposure in environmental cancer epidemiology. Cancer Detect.
    23. (2000). Carcinogen macromolecular adducts and their measurement. Carcinogenesis
    24. (1997). Cigarette smoking induces an increase in oxidative DNA damage, 8-hydroxydeoxyguanosine, in a central site of the human lung. Carcinogenesis
    25. (2008). Clinical cancer control and prevention. Eliminating tobacco-induced cancers: a worldwide challenge.
    26. (1986). Committee on passive smoking. National Academy Press:
    27. (1996). Comparative synchronous fluorescence spectrophotometry and 32P-postlabeling analysis of PAH-DNA adducts in human lung and the relationship to TP53 mutations.
    28. (2004). Comparison of DNA adduct levels in nasal mucosa, lymphocytes and bronchial mucosa of cigarette smokers and interaction with metabolic gene polymorphisms. Carcinogenesis
    29. (1988). Correlation of DNA adduct levels in human lung with cigarette smoking.
    30. (1995). Correlation of DNA adducts in blood mononuclear cells with tobacco carcinogen-induced damage in human lung. Cancer Res.
    31. (1995). Demonstration of smoking-related DNA damage in cervical epithelium and correlation with human papillomavirus type 16, using exfoliated cervical cells.
    32. (1991). Detection of carcinogen-DNA adducts in exfoliated urothelial cells of cigarette smokers: association with smoking, hemoglobin adducts, and urinary mutagenicity. Cancer Epidemiol. Biomarkers Prev.
    33. (1997). Detection of DNA modifications by the 32P-postlabelling assay. Mutat Res.
    34. (1998). Differences in aromatic-DNA adduct levels between alveolar macrophages and subpopulations of white blood cells from smokers, Carcinogenesis
    35. (2000). DNA adduct level in lung tissue may act as a risk biomarker of lung cancer.
    36. (2005). DNA adducts and lung cancer risk: a prospective study. Cancer Res.
    37. (2005). DNA adducts as markers of exposure and
    38. (2000). DNA adducts as markers of exposure to carcinogens and risk of cancer.
    39. (1998). DNA adducts in human pancreatic tissues and their potential role in carcinogenesis Cancer Res.
    40. (1991). DNA adducts in lymphocytes and granulocytes of smokers and nonsmokers detected by the 32P-postlabelling assay. Carcinogenesis
    41. (2003). DNA adducts in normal bladder tissue and bladder cancer risk. Mutagenesis
    42. (2009). DNA adducts, genetic polymorphisms, and K-ras mutation in human pancreatic cancer.
    43. (2000). Dna adducts, mutations, and cancer
    44. (1993). DNA strand breakage and DNA adducts in lymphocytes of oral cancer patients. Carcinogenesis
    45. (1995). Effects of smoking marijuana, tobacco or cocaina alone or in combination on DNA damage in human alveolar macrophages. Life Sci.
    46. (2000). Expression of CYP1A1, CYP1B1 and CYP3A and polycyclic aromatic hydrocarbon-DNA adduct formation in bronchoalveolar macrophages of smokers and non-smokers.
    47. (2008). Gene-environment interaction in tobacco-related cancers. Carcinogenesis
    48. (1997). Genotypes of glutathione transferase M1 and P1 and their significance for lung DNA adduct levels and cancer risk. Carcinogenesis
    49. (1999). GSTP1, CYP1A1 and CYP2D6 polymorphisms in lung cancer patients from an environmentally polluted region of Poland: correlation with lung DNA adduct levels.
    50. (1998). High benzo[a]pyrene diol-epoxide DNA adduct levels in lung and blood cells from individuals with combined CYP1A1 MspI/Msp-GSTM1*0/*0 genotypes. Pharmacogenetics
    51. (1999). Hprt mutant frequency and aromatic DNA adduct level in nonsmoking and smoking lung cancer patients and population controls. Carcinogenesis
    52. (2006). Interindividual variations in DNA adduct levels assessed by analysis of multiple genetic polymorphisms in smokers. Cancer Epidemiol. Biomarkers Prev.
    53. (2000). Levels of 8-hydroxydeoxyguanosine as a marker of DNA damage in human leukocytes. Free Radic.
    54. (1986). Modern Epidemiology. Little Brown & Co:
    55. (2001). Modulation of DNA and protein adducts in smokers by genetic polymorphisms
    56. (1995). Molecular epidemiology and human risk monitoring.
    57. (1992). Molecular epidemiology in cancer risk assessment and prevention: recent progress and avenues for future research. Environ. Health Perspec.
    58. (1986). Mutations activating human c-Ha-ras1 protooncogene (HRAS) induced by chemical carcinogens and depurination.
    59. (2004). Myeloperoxidase (MPO) -463G->A reduces MPO activity and DNA adduct levels in bronchoalveolar lavages of smokers. Cancer Epidemiol. Biomarkers Prev.
    60. (1998). Oxidative stress induced by environmental tobacco smoke in the workplace is mitigated by antioxidant supplementation Cancer Epidemiol. Biomarkers Prev.
    61. (1992). Polycyclic aromatic hydrocarbon--DNA adducts in white blood cells from lung cancer patients: no correlation with adduct levels in lung. Carcinogenesis
    62. (2008). Progress and challenges in selected areas of tobacco carcinogenesis.
    63. (2008). Second-hand smoke and human lung cancer. Lancet Oncol.
    64. (2006). Sex differences in risk of lung cancer: Expression of genes in the PAH bioactivation pathway in relation to smoking and bulky DNA adducts.
    65. (2004). Sidestream tobacco smoke as the main predictor of exposure to polycyclic aromatic hydrocarbons.
    66. (1998). Smoking-associated bulky DNA adducts in bronchial tissue related to CYP1A1 MspI and GSTM1 genotypes in lung patients. Carcinogenesis
    67. The health consequences of involuntary smoking: a report of the Surgeon General. Publication N. DHHS (CDC) 87-(8398). Government Printing Office:
    68. (1995). The impact of glutathione s-transferase M1 and cytochrome P450 1A1 genotypes on white-blood-cell polycyclic aromatic hydrocarbon-DNA adduct levels in humans.
    69. (2007). The molecular epidemiology of lung cancer. Carcinogenesis
    70. (2004). The pathophysiology of cigarette smoking and cardiovascular disease: an update.
    71. (2000). White blood cell DNA adducts and fruit and vegetable consumption in bladder cancer. Carcinogenesis

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.